In addition to the CRO services, part of our effort is concentrated on initiating collaborative research projects with biotech industries and academic institutions. Troubleshooting is an integral part of custom synthesis and the delivery is time bound. We believe that a constant enhancement of our technical knowledge through research would enable us to stay on par with the competition These research collaborations would focus on developing new synthetic methodologies and catalysts which could be utilized later in the custom synthesis projects.

We are in the process of initiating collaboration with a leading academic institution which offers complementary expertise and facilities in the area of drug discovery. Our broad interest lies in the area of cancer biology and neurodegenerative diseases. We would focus on the diversity-oriented synthesis of novel, SP3 rich and topologically diverse compound libraries which could be tested in phenotypic assays or against a specific target of interest. Currently, we hold a compound library based on sulfoximines which are gaining importance as a key pharmacophore in organic synthesis.   We are also in the process of developing new catalysts based on main group metals that could be utilized in the synthesis of organic molecules.

In addition to the CRO services, part of our effort is concentrated on initiating collaborative research projects with biotech industries and academic institutions. Trouble shooting is an integral part of custom synthesis and the delivery is time bound. We believe that, a constant enhancement of our technical knowledge through research would enable us to stay on par with the competition These research collaborations would focus on developing new synthetic methodologies and catalysts which could be utilized later in the custom synthesis projects.

We are in the process of initiating collaboration with a leading academic institution which offers a complimentary expertise and facilities in the area of drug discovery. Our broad interest lies in the area of cancer biology and neurodegenerative diseases. We would focus on the diversity oriented synthesis of novel, SP3 rich and topologically diverse compound libraries which could be tested in phenotypic assays or against a specific target of interest. Currently we hold a compound library based on sulfoximines which are gaining importance as a key pharmacophore in organic synthesis.   We are also in the process of developing new catalysts based on main group metals that could be utilized in the synthesis of organic molecules.